|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||4.0600 - 4.1550|
|52-week range||4.0600 - 4.1550|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||N/A|
|Earnings date||14 Nov 2022 - 18 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.